ribavirin has been researched along with Anemia in 262 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.76) | 18.7374 |
| 1990's | 3 (1.15) | 18.2507 |
| 2000's | 89 (33.97) | 29.6817 |
| 2010's | 165 (62.98) | 24.3611 |
| 2020's | 3 (1.15) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
| Calil-Elias, S; Crisante, VC; Cursino, CN; de Almeida, RMVR; Duarte, GDS; Giordani, F; Monteiro, PGO; Vieira, TBQ; Xavier, AR | 1 |
| Du, P; Li, X; Ma, Z; Sun, Y | 1 |
| Bider-Canfield, Z; Cheetham, TC; Gharibian, D; Latt, NL; Louie, V; Mittal, R; Sahota, A; Yanny, BT | 1 |
| Abdelhafez, AT; Cusato, J; D'Avolio, A; De Nicolo, A; Di Perri, G; El Desoky, ES; Hussein, AM; Kamel, SI | 1 |
| Ahmad, W; Alam, SE; Asif, M; Hussain Jaffery, SS; Sajjad, SF | 1 |
| Ashraf, M; Bukhsh, A; Gul, A; Khiljee, S; Omer, MO; Rafique, G | 1 |
| Bodeau, S; Brochot, E; Domange, B; Duverlie, G; Garçon, L; Handala, L; Helle, F; Nguyen-Khac, E; Ouled-Haddou, H | 1 |
| Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH | 1 |
| Otori, K; Tanaka, Y; Yokomori, H | 1 |
| Deng, J; Duan, Z; Fan, D; Wei, B; Zhu, C | 1 |
| Häffner, K; Klämbt, V; Panning, M; Pohl, M; Seidl, M | 1 |
| Cheung, CYS; Cooper, SE; Liu, HY | 1 |
| Agarwal, K; Cannon, MD; Carey, I; Childs, K; Considine, A; Dusheiko, G; Manini, MA; Mazzarelli, C; Suddle, A | 1 |
| Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ | 1 |
| Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N | 1 |
| Afify, S; Alboraie, M; Algaber, MA; Doss, W; El Halwagy, H; El Kassas, M; El Latif, YA; El Tahan, A; Elsaeed, K; Elserafy, M; Omar, H | 1 |
| Graf, C; Herrmann, E; Mücke, MM; Mücke, VT; Vermehren, J; Zeuzem, S | 1 |
| Amory, C; Gardenier, D; Weiss, JJ; Woody, A | 1 |
| Chi, X; Gao, X; Jiang, J; Jiang, T; Niu, J; Pan, Y; Wang, M; Wang, X; Wu, R; Yan, H | 1 |
| Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM | 1 |
| Andreoletti, M; Borroni, G; Cazzaniga, M; Ceriani, R; Guerzoni, P; Omazzi, B; Pich, MG; Prada, A; Salerno, F; Spinzi, G; Terreni, N | 1 |
| Bruha, R; Dusek, L; Kreidlova, M; Marecek, Z; Petrtyl, J; Urbanek, P | 1 |
| Backus, LI; Belperio, PS; Cheung, RC; Hwang, EW; Mole, LA; Thomas, IC | 1 |
| Aboalam, H; Ahmed, WH; Eldin, AS; Furusyo, N; Hayashi, J; Murata, M; Ogawa, E; Zaky, S | 1 |
| Geng, JX; Zhang, JM; Zhang, Q | 1 |
| Boonstra, A; De Knegt, RJ; Groothuismink, ZM; Janssen, HL; Koning, L; Roomer, R; Spaan, M | 1 |
| Aguilera, V; Berenguer, M; Vinaixa, C | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 2 |
| Abbas, SM; El-Feky, HM; Hegab, MF; Lashin, AH; Metwally, MA; Shaheen, YA | 1 |
| Beinhardt, S; Datz, C; Ferenci, P; Hofer, H; Laferl, H; Maieron, A; Rutter, K; Scherzer, TM; Schwarzer, R; Stättermayer, AF; Stauber, R; Steindl-Munda, P; Strasser, M | 1 |
| Berenguer, M; Calleja, JL; Molina, E; Romero-Gómez, M | 1 |
| Aichelburg, MC; Breitenecker, F; Grabmeier-Pfistershammer, K; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Scheiner, B; Trauner, M | 1 |
| Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S | 1 |
| Boglione, L; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Rizzetto, M; Smedile, A; Strona, S; Troshina, G | 1 |
| Arakawa, T; Hige, S; Karino, T; Kimura, M; Kuwata, Y; Nakajima, T; Ohmura, T; Ozeki, I; Sato, T; Toyota, J | 1 |
| Bichoupan, K; Branch, A; Brinkley, S; Dieterich, D; Martel-Laferrière, V; Perumalswami, P; Posner, S; Schiano, T; Stivala, A; Sulkowski, M | 1 |
| Pol, S | 1 |
| Albrecht, JK; Brass, CA; Clark, PJ; Gordon, SC; Jazwinski, AB; Lawitz, EJ; Muir, AJ; Noviello, S; Pedicone, LD; Sulkowski, MS; Thompson, AJ | 1 |
| Planas, R; Tural, C | 1 |
| Inao, M; Mochida, S; Nakayama, N; Sugawara, K | 1 |
| Hézode, C | 2 |
| Bansal, M; Bichoupan, K; Branch, AD; Crismale, JF; Dieterich, DT; Liu, LU; Martel-Laferrière, V; Odin, JA; Pappas, A; Perumalswami, PV; Schiano, TD; Schonfeld, E; Wyatt, C | 1 |
| Baragli, F; Corti, G; Salomoni, E | 1 |
| Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM | 1 |
| Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML | 1 |
| Aghemo, A; Clark, PJ; Colombo, M; D'Ambrosio, R; Degasperi, E; Galmozzi, E; Muir, AJ; Patel, K; Rumi, MG; Thompson, AJ; Urban, TJ; Vock, DM | 1 |
| Bodeau, S; Brochot, E; Duverlie, G; Nguyen-Khac, E | 1 |
| Eder, E; Ferenci, P; Hofer, H; Scherzer, TM | 1 |
| Baldini, A; Coate, B; DeMasi, R; Luo, D; Mrus, J; Witek, J; Zeuzem, S | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Brogan, AJ; Deniz, B; Miller, JD; Rubin, J; Talbird, SE; Thompson, JR | 1 |
| Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Lee, CY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML | 1 |
| Aghemo, A; Cappellini, MD; Colancecco, A; Colombo, M; Monico, S; Porretti, L; Prati, G; Ronzoni, L; Rumi, MG | 1 |
| Enomoto, N; Fujiwara, K; Izumi, N; Joh, T; Kurosaki, M; Kusakabe, A; Matsuura, K; Mizokami, M; Nojiri, S; Orito, E; Sakamoto, N; Shinkai, N; Tanaka, Y; Watanabe, T; Yatsuhashi, H | 1 |
| Aghemo, A; Castaldi, D; Colombo, M; D'Ambrosio, R; Degasperi, E; Galmozzi, E; Grassi, E; Rumi, MG; Soffredini, R | 1 |
| Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inui, Y; Kaneko, A; Kasahara, A; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Suzuki, K; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yamada, R; Yoshida, Y; Yoshihara, H | 1 |
| Angeli, E; Caputo, A; Cattelan, AM; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G | 1 |
| Smolić, M; Smolić, R; Vcev, A | 1 |
| Arotçarena, R; Causse, X; Denis, J; Hagège, H; Henrion, J; Lesgourgues, B; Nalet, B; Pariente, A; Rémy, AJ | 1 |
| Bruzzi, P; Girardi, E; Ippolito, G; Lanini, S; Mammone, A; Puro, V | 1 |
| Cheng, HS; Hung, CH; Hung, IW; Hwang, JJ; Lin, CH; Lo, CC; Tsai, WJ | 1 |
| Andrade, RJ; Buti, M; Casado, MA; Gros, B; Oyagüez, I; Serra, MA; Turnes, J | 1 |
| Beumont-Mauviel, M; De La Rosa, G; Forns, X; Fried, MW; Fu, M; Jacobson, IM; Jessner, W; Kalmeijer, R; Lenz, O; Manns, MP; Ouwerkerk-Mahadevan, S; Peeters, M; Poordad, F; Scott, JA; Sinha, R; Zeuzem, S | 1 |
| Anan, A; Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kitamura, Y; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Tsuchiya, N; Watanabe, H; Yokoyama, K; Yoshikane, M; Yotsumoto, K | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kouno, M; Kudo, M; Minami, Y; Takita, M; Ueshima, K; Yada, N | 1 |
| Arbuckle, R; Beumont, M; Brohan, E; Fu, M; Gilles, L; Jessner, W; Panter, C; Scott, J | 1 |
| Bennis, Y; Bodeau, S; Brochot, E; Capron, D; Duverlie, G; Nguyen-Khac, E; Solas, C | 1 |
| Gattei, V; Mauro, E; Mazzaro, C | 1 |
| Aboulker, JP; Barrail-Tran, A; Chevaliez, S; Cotte, L; Fournier, I; Lacombe, K; Molina, JM; Taburet, AM; Valantin, MA; Vincent, C | 1 |
| Antinori, S; Calvi, E; Cheli, S; Clementi, E; D'Avolio, A; De Nicolò, A; Falvella, FS; Magni, C; Mazzali, C; Milazzo, L; Peri, AM | 1 |
| Akamatsu, N; Aoki, T; Harada, N; Hasegawa, K; Ishizawa, T; Kaneko, J; Kokudo, N; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Yamaguchi, T | 1 |
| Arends, JE; Dabis, F; Fontaine, H; Gilbert, C; Lacombe, K; Loko, MA; Miailhes, P; Puoti, M; Rockstroh, JK; Rosenthal, E; Salmon, D; Sogni, P; Winnock, M; Wittkop, L | 1 |
| Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Ahn, SB; Choe, WH; Chung, JI; Jun, DW; Jung, KS; Kim, DY; Kim, JK; Kim, SG; Kim, W; Lee, SH; Park, SY; Seo, YS; Shim, JJ; Shin, HP | 1 |
| Cao, WC; Cui, N; Fan, YD; Guo, CT; Hu, JG; Liu, W; Lu, QB; Qin, SL; Wang, HY; Wang, LY; Yang, ZD; Zhang, SY; Zhang, XA | 1 |
| Albillos, A; Hernández-Guerra, M; Luis Calleja, J; Molina, E; Planas, R; Romero-Gómez, M; Turnes, J | 1 |
| Egawa, H; Hashimoto, E; Kogiso, T; Kotera, Y; Omori, A; Shiratori, K; Taniai, M; Tokushige, K; Yamamoto, M | 1 |
| Bakker, JA; Bierau, J; de Knegt, RJ; Leers, MP; Peltenburg, NC; Verbon, A; Vroemen, WH | 1 |
| Bushman, LR; Jimmerson, LC; Kiser, JJ; Kottilil, S; McHutchison, JG; Meissner, EG; Osinusi, A; Petersen, T; Rower, JE; Sims, Z; Wolfe, P | 1 |
| Ampuero, J; Andrade, RJ; Buti, M; Cabezas, J; Calleja, JL; Crespo, J; Del Campo, JA; Fernández, I; Forns, X; Lens, S; Millán, R; Rojas, L; Romero-Gómez, M | 1 |
| Alberti, A; De Franceschi, L; Dissegna, D; Donato, F; Fattovich, G; Ieluzzi, D; Iolascon, A; Lupo, F; Matté, A; Piovesan, S; Raffetti, E; Russo, R; Siciliano, A; Toniutto, P; Turrini, F; Zuliani, V | 1 |
| Adinolfi, LE; Alessio, L; Boemio, A; Coppola, N; Grandone, A; Marrone, A; Minichini, C; Pisaturo, M; Sagnelli, E; Stanzione, M; Starace, M; Zampino, R | 1 |
| Kalsekar, A; Le, TK; Macaulay, D; Sorg, RA; Wei, J; Wu, EQ; Yuan, Y | 1 |
| Almeida, AJ; Brandão-Mello, CE; Coelho, HS; Costa, MM; Costa, VD; Delvaux, N; Esberard, EB; Flores, PP; Lampe, E; Villar, LM; Villela-Nogueira, CA | 1 |
| Besma, YL; Brochot, E; Gazouani, E; Morel, V; Mouelhi, L; Sghaier, I | 1 |
| Cheli, S; Clementi, E; Falvella, FS; Landonio, S; Lombardi, A; Magni, C; Mazzali, C; Mondelli, MU; Rizzardini, G | 1 |
| Burger, DM; Buti, M; de Kanter, CT; DeMasi, R; Dofferhoff, AS; Drenth, JP; Ouwerkerk-Mahadevan, S; Witek, J; Zeuzem, S | 1 |
| Asselah, T; Baum, P; Böcher, WO; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Mensa, FJ; Müllhaupt, B; Roberts, SK; Schuchmann, M; Soriano, V; Stern, JO; Voss, F; Zeuzem, S | 1 |
| Boyer-Darrigand, N; D'alteroche, L; Dao, MT; Ducancelle, A; Fouchard-Hubert, I; Larrey, D; Le Guillou-Guillemette, H; Loustaud-Ratti, V; Lunel-Fabiani, F; Picard, N; Saulnier, P; Veillon, P | 1 |
| Chayama, K; Imamura, M | 1 |
| Kishk, R; Mandour, M; Nemr, N | 1 |
| D'Argenio, DZ; Jimmerson, LC; Kiser, JJ; MacBrayne, CE; Wu, LS | 1 |
| Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R | 1 |
| Ahlers, S; Bakalos, G; Coppola, C; Derbala, M; Ferenci, P; Foster, GR; Hassanein, T; Orlandini, A; Reddy, KR; Shiffman, ML; Tallarico, L | 1 |
| Barrail-Tran, A; Bellissant, E; Bourlière, M; Cotte, L; Fournier, I; Garraffo, R; Kheloufi, F; Lacarelle, B; Molina, JM; Poizot-Martin, I; Quaranta, S; Renault, A; Solas, C | 1 |
| Christensen, P; Dalgard, O; Färkkilä, M; Krarup, H; Lagging, M; Lindahl, K; Nilsson, S; Norkrans, G; Norrgren, H; Nyström, K; Rauning Buhl, M; Stenmark, S; Waldenström, J; Westin, J | 1 |
| Goncales, ES; Goncales, FL; Lazarini, MS; Mendes, LC; Miotto, N; Pedro, MN; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Geier, A; Kuhn, S; Kuntzen, D; Kuntzen, T; Müllhaupt, B; Seifert, B | 1 |
| Ampuero, J; Romero-Gómez, M | 1 |
| Berden, FA; Blokzijl, H; de Knegt, RJ; den Hollander, J; Drenth, JP; Friederich, P; Kievit, W; Kuiken, SD; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, CM; van Vonderen, MG; Willemse, SB | 1 |
| Anthony, DD; Bonomo, RA; Chandar, AK; Compan, A; Davitkov, P; Falck-Ytter, Y; Gideon, C; Hirsch, A; Silveira, MG; Smith, S | 1 |
| Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P | 1 |
| Bodeau, S; Brochot, E; Diouf, M; Duverlie, G; Lemouel, JP; Nguyen-Khac, E | 1 |
| Ascione, T; Borgia, G; Buonomo, AR; Calò, F; Coppola, N; De Pascalis, S; de Stefano, G; Di Caprio, G; Federico, A; Filippini, P; Gaeta, GB; Gentile, I; Martini, S; Messina, V; Minichini, C; Persico, M; Rinaldi, L; Sangiovanni, V; Stanzione, M; Starace, M; Stornaiuolo, G; Zampino, R | 1 |
| Camacho, F; Cooper, CL; Costiniuk, CT | 1 |
| Kristian, P; Pellová, A; Porubcin, S; Schréter, I | 1 |
| Fried, MW; Hadziyannis, SJ; Jensen, DM; Messinger, D; Reau, N | 1 |
| Davison, SM; Kelly, DA | 1 |
| Kearney, KR; Navarro, VJ; Thornton, JJ | 1 |
| Nelson, DR; Reddy, KR; Zeuzem, S | 1 |
| Ferenci, P | 1 |
| Guindi, M; Kirby, M; O'Connor, C; Roberts, EA; Yap, J | 1 |
| Esposito, L; Guitard, J; Kamar, N; Ribes, D; Rostaing, L | 1 |
| Alba, LM; Bulchandani, D; Nachnani, JS; Pandya, PK; Rao, GA | 1 |
| Gomollón García, F; Moreno López, R; Sicilia Aladrén, B | 1 |
| Brok, J; Gluud, C; Gluud, LL | 1 |
| Chun, E; Gish, RG; Gitlin, N; Halliman, DG; Heise, J; Marcellin, P; Rodriguez-Torres, M | 1 |
| Falasca, K; Gorgoretti, V; Mancino, P; Pizzigallo, E; Ucciferri, C; Vecchiet, J | 1 |
| Bishop, R; Cortez, KJ; Kottilil, S; Masur, H; McLaughlin, M; Murphy, A; Osinusi, A; Polis, MA; Proschan, M; Rasimas, JJ; Rosenstein, D | 1 |
| Mac Nicholas, R; Norris, S | 1 |
| Cozma, A; Orāşan, O; Pârvu, A; Petrov, L; Rednic, N; Sâmpelean, D | 1 |
| Alsaran, K; Sabry, A; Shaheen, N | 1 |
| Abe, H; Chayama, K; Hayashida, Y; Hayes, CN; Kubo, M; Kumada, H; Maekawa, T; Nakamura, Y; Nakano, R; Ochi, H; Tsunoda, T | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Deng, W; Harrison, SA; Herrine, SK; Koury, K; Lee, WM; McCone, J; McHutchison, JG; Noviello, S; Pedicone, LD; Poordad, FF; Reddy, KR; Shiffman, ML; Sulkowski, MS | 1 |
| Boland, GJ; Burger, DM; Drenth, JP; Janssen, MP; Siersema, PD; Van Erpecum, KJ; Van Soest, H; Van Vlerken, LG | 1 |
| Dixit, V; Fabrizi, F; Martin, P; Messa, P | 1 |
| Cirulli, ET; Fellay, J; Goldstein, DB; Gumbs, CE; Hitomi, Y; McHutchison, JG; Shianna, KV; Thompson, AJ; Urban, TJ | 1 |
| Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kamatani, N; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Nakamura, Y; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Clark, PJ; Facciorusso, D; Goldstein, DB; Mangia, A; McHutchison, JG; Mottola, L; Muir, AJ; Naggie, S; Patel, K; Petruzzellis, D; Piazzolla, V; Romano, M; Santoro, R; Shianna, KV; Sogari, F; Thompson, AJ; Tillmann, HL | 1 |
| van Erpecum, KJ; van Oijen, MG; van Vlerken, LG | 1 |
| Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Bronowicki, JP; Bruno, S; DiNubile, MJ; Goodman, ZD; Jacobson, IM; Manns, MP; McCone, J; Poordad, F; Reddy, KR; Sniukiene, V; Sulkowski, MS | 1 |
| Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Burroughs, M; Esteban, R; Goodman, ZD; Gordon, SC; Lawitz, E; Marcellin, P; Poordad, F; Sings, HL; Vierling, JM; Zeuzem, S | 1 |
| Jensen, DM | 1 |
| Cheng, W; Crawford, DH; Depamphilis, JK; Dore, GJ; McCaughan, GW; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Weltman, M; Yoshihara, M | 1 |
| Abe, H; Akuta, N; Azakami, T; Chayama, K; Hayes, CN; Imamura, M; Kamatani, N; Kawakami, Y; Kobayashi, M; Kumada, H; Miki, D; Nakamura, Y; Ochi, H; Sezaki, H; Suzuki, F; Takahashi, S; Tsuge, M | 1 |
| Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML | 1 |
| Andersen, JW; Butt, AA; Chung, RT; Sherman, KE; Umbleja, T | 1 |
| Akaike, J; Arakawa, T; Chayama, K; Kamiya, N; Karino, Y; Kumada, H; Kuwata, Y; Ohmura, T; Ozeki, I; Sato, T; Toyota, J; Yamada, I | 1 |
| Alain, S; Babany, G; Bourlière, M; Carrier, P; De Ledinghen, V; Di Martino, V; Loustaud-Ratti, V; Marquet, P; Maynard, M; Pinta, A; Pol, S; Rousseau, A; Sautereau, D; Trépo, C; Zarski, JP | 1 |
| Cabrera, R; Draganov, PV; Limaye, AR | 1 |
| Aguilera, V; Berenguer, M; Giusto, M; López-Andujar, R; Navarro, L; Ortiz, C; Prieto, M; Rodriguez, M; Rubin, A; San-Juan, F | 1 |
| Aberg, JA; Aboulafia, D; Bonilla, H; Dimova, R; Doonquah, L; Dove, L; Galpin, J; Glesby, MJ; Hassanein, T; Jacobson, IM; Johnston, B; Liu, RC; Pearce, D; Rodriguez, J; Talal, AH; Zeremski, M | 1 |
| Attili, AF; Biliotti, E; Corradini, SG; Gentili, F; Giannelli, V; Giusto, M; Lionetto, L; Merli, M; Rossi, M; Simmaco, M; Taliani, G | 1 |
| Adda, N; Adler, M; Afdhal, NH; Everson, GT; Flamm, SL; Fried, MW; George, S; Kauffman, RS; Martin, M; Nelson, DR; Poordad, F; Reesink, HW; Sankoh, AJ; Sherman, KE; Sulkowski, MS; Wright, CI | 1 |
| Aguirrebengoa, K; Barreiro, P; Benito, JM; Castro, MÁ; Labarga, P; Miralles, C; Miralles, P; Morello, J; Ocampo, A; Pineda, JA; Portu, J; Rallón, NI; Rodríguez-Nóvoa, S; Soriano, V; Tellez, MJ; Vispo, E | 1 |
| Andoh, A; Aomatsu, T; Fujiyama, Y; Imaeda, H; Nishimura, T; Okumura, Y; Osaki, R; Shioya, M; Takeuchi, T | 1 |
| Buti, M; Homs, M | 1 |
| Calle Serrano, B; Cornberg, M; Manns, MP; Markova, AA | 1 |
| Forestier, N; Zeuzem, S | 1 |
| Bacon, BR; Khalid, O | 1 |
| Esteban, R; Shiffman, ML | 1 |
| Buti, M; Esteban, R; Simón-Talero, M | 1 |
| De Gottardi, A; Geier, A; Gerlach, T; Heim, M; Helbling, B; Hirschi, C; Negro, F; Stickel, F; Terziroli, B; Wehr, K | 1 |
| Alavian, SM; Behnava, B; Tabatabaei, SV | 1 |
| Chien, CH; Chien, RN; Hu, CC; Kuo, YL; Lin, CL; Lin, CY; Tien, HC; Weng, CH; Yen, CL | 1 |
| Inage, E; Minowa, K; Naritaka, N; Ohtsuka, Y; Saito, N; Shimizu, T; Suzuki, M; Tokita, A; Tsubahara, M | 1 |
| Abbott, D; Lee, HK; Trask, LE | 1 |
| Baiget, M; Del Mar Gutierrez, M; Domingo, P; Fontanet, A; Guardiola, JM; Lamarca, K; Martin, J; Mateo, MG; Muñoz, J; Pacho, C; Salazar, J; Torres, F; Vidal, F | 1 |
| Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakamoto, N; Sho, T; Terashita, K | 1 |
| Fazio, V; Giannini, EG; Marenco, S; Picciotto, A; Pieri, G; Savarino, V | 1 |
| Casey, LC; Lee, WM | 1 |
| Afendy, A; Baranova, A; Birerdinc, A; Estep, M; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Fishbein, D; Funk, E; Hu, Z; Kottilil, S; Masur, H; Naggie, S; Osinusi, A; Polis, M; Poonia, S; Schlaak, J; Trippler, M | 1 |
| Berak, H; Dusheiko, GM; Ferenci, P; Gane, EJ; Hadziyannis, SJ; Han, KH; Harley, HA; Horsmans, YJ; Husa, P; Jenny Heathcote, E; Lee, SS; Messinger, D; Roberts, SK; Tatsch, F | 1 |
| Amanzada, A; Lindhorst, A; Mihm, S; Moriconi, F; Ramadori, G; Schneider, S; Suermann, T; van Thiel, DH | 1 |
| Adinolfi, LE; Barillari, M; Costa, G; Marrone, A; Zampino, R | 1 |
| Dixit, NM; Krishnan, SM | 1 |
| Chang, CK; Hsieh, YH; Hung, TH; Lai, NS; Tseng, CW; Tseng, KC; Wu, SF | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Bronowicki, JP; Burroughs, MH; Harrison, SA; Jacobson, IM; Koury, KJ; Manns, MP; Pedicone, LD; Poordad, F; Rajender Reddy, K; Sings, HL; Sniukiene, V; Sulkowski, MS | 1 |
| Abe, H; Agata, R; Aizawa, Y; Fujise, K; Ika, M; Matsudaira, H; Nagatsuma, K; Namiki, Y; Shimada, N; Tada, N; Tsubota, A; Yoshizawa, K; Yumoto, Y | 1 |
| Dumortier, J; Gagnieu, MC; Guillaud, O; Janbon, B; Juillard, L; Leroy, V; Morelon, E | 1 |
| Kwo, PY | 1 |
| Becker, PP; Dill, MT; Dufour, JF; Geier, A; Manser, CN; Moradpour, D; Müllhaupt, B; Rau, M; Russmann, S; Schmitt, J; Semela, D; Stickel, F; Weisskopf, M | 1 |
| Asahina, Y; Enomoto, N; Izumi, N; Kurosaki, M; Maekawa, S; Matsuura, K; Mizokami, M; Nakagawa, M; Nishida, N; Sakamoto, M; Sakamoto, N; Tanaka, Y; Tokunaga, K; Watanabe, M | 1 |
| Heil, EL; Hynicka, LM | 1 |
| Ascione, T; Bruno, R; Campanone, A; De Sena, R; Felaco, FM; Filice, G; Gaeta, GB; Piccinino, F; Precone, DF; Spadaro, A; Stanzione, M; Stornaiuolo, G | 1 |
| Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Ogata, K; Okamura, T; Sata, M; Seki, R; Tanaka, K | 1 |
| Fouchard-Hubert, I; Gergely, AE; Lunel-Fabiani, F | 1 |
| Sulkowski, MS | 2 |
| Bini, EJ; Bowers, PJ; Bräu, N; Dieterich, DT; Hassanein, TI; Sulkowski, MS; Wasserman, R | 1 |
| Bruchfeld, A; Lindahl, K; Schvarcz, R; Ståhle, L | 2 |
| Homma, M; Inoue, Y; Kohda, Y; Matsuzaki, Y; Mitamura, K; Shibata, M; Tanaka, N | 1 |
| Afdhal, NH | 1 |
| Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, T; Younossi, Z | 1 |
| Alarcón, C; Arambarri, M; Echarri, R; Fernández Lucas, M; Merino, JL; Ortuño, J; Teruel, JL | 1 |
| Trivedi, HS; Trivedi, M | 1 |
| Izumi, N | 1 |
| Ong, JP; Younossi, ZM | 1 |
| Gonzalez, SA; Jacobson, IM | 1 |
| Collantes, R; Gujral, H; Viscomi, C | 1 |
| Altintas, E; Sezgin, O | 1 |
| Kostman, JR; Lo Re, V | 1 |
| Chung, RT; Yachimski, P | 1 |
| Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Leitz, G; Mody, SH; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, TL; Younossi, Z | 1 |
| Balan, V; Bowers, PJ; Burnett, A; Ghalib, R; Goon, BL; Jackson, J; Keeffe, EB; Leitz, GJ; Muir, AJ; Rossaro, L; Schwartz, D; Wu, GY | 1 |
| Alaric, L; Bureau, C; Péron, JM; Pey, F; Valmary, S; Vinel, JP; Zabraniechki, L | 1 |
| Bouton, V; Boyer, N; Farcy-Afif, M; Marcellin, P; Sinègre, M; Stocco, J; Tod, M | 1 |
| Motoo, Y; Mouri, H; Ohtsubo, K; Sawabu, N; Watanabe, H; Yamaguchi, Y | 1 |
| Buttrey, MJ; Chiou, HE; Kuo, HP; Kuo, HT; Liu, CL; Liu, HW; Lu, YT | 1 |
| Barreiro, P; García-Samaniego, J; González-Lahoz, J; Jiménez-Nácher, I; Martín-Carbonero, L; Núñez, M; Rendón, AL; Romero, M; Soriano, V | 1 |
| Alvarez, D; Bini, EJ; Bräu, N; Dejesus, E; Dieterich, DT; Leitz, GJ; Sulkowski, MS | 1 |
| Afdhal, NH; Curry, MP | 1 |
| Grattagliano, I; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S | 1 |
| Broissand, C; Fontaine, H; Lebray, P; Nalpas, B; Pol, S; Serpaggi, J; Sobesky, R; Vallet-Pichard, A | 1 |
| Chen, K; Chiou, CF; Robbins, S; Spiegel, BM; Younossi, ZM | 1 |
| Crone, C; Dan, AA; Farmer, DW; Martin, LM; Ong, JP; Robbins, SC; Wise, T; Younossi, ZM | 1 |
| Boyanova, Y; Calmus, Y; Conti, F; Pissaia, A; Soubrane, O | 1 |
| Chao, YC; Chen, CL; Chen, DS; Chen, PJ; Hsiao, TJ; Hsieh, TY; Hu, JT; Kao, JH; Lai, MY; Liao, LY; Lin, CL; Liu, CJ; Yang, SS | 1 |
| Becker, MC; Bresson-Hadni, S; Bronowicki, JP; Di Martino, V; Lunel-Fabiani, F; Miguet, JP; Thevenot, T; Vanlemmens, C | 1 |
| Longo, DL; Manns, MP; McHutchison, JG | 1 |
| Asnis, GM; De La Garza, R | 1 |
| Alvarez, D; Ball, L; Brau, N; Dieterich, DT; Moorehead, L; Sulkowski, MS | 1 |
| Dolmazashvili, E; Gochitashvili, N; Kakabadze, T; Sharvadze, L; Tsertsvadze, T | 1 |
| Deschênes, M; Hilzenrat, N; Nudo, CG; Wong, P | 1 |
| Chang, KC; Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Lee, CM; Lu, SN; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Duff, F; Jorga, K; Lamb, M; Snoeck, E; Wade, JR | 1 |
| Del Rio, RA; Post, AB; Singer, ME | 1 |
| Grattagliano, I; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S | 1 |
| Bardadin, K; Berak, H; Horban, A; Paprocka, H; Stańczak, JJ; Wasilewski, M | 1 |
| Bowers, P; Henry, DH; Lamarca, A; Leitz, G; Slim, J | 1 |
| Dar Santos, AE; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Gra Oramas, B; Llanio Navarro, R; Ruenes Domech, C; Soler, E; Vilar Gomez, E | 1 |
| Dresser, L; Loeb, M; Louie, M; Mazzulli, T; McGeer, A; Muller, MP; Raboud, J; Rea, E; Richardson, SE | 1 |
| Brown, RS; Manns, MP; McHutchison, JG; Reddy, KR; Shiffman, ML; Wong, JB | 1 |
| Ambühl, PM; Calanca, LN; Fehr, T; Fischer-Vetter, J; Jochum, W; Müllhaupt, B; Wüthrich, RP | 1 |
| Arora, S; Gish, RG; Murphy, B; Nelson, DR; O'Brien, C; Rajender Reddy, K; Xu, Y | 1 |
| Benhamou, Y; Sulkowski, MS | 1 |
| Benhamou, Y | 1 |
| Cross, JT; Devine, EB; Kowdley, KV; Sullivan, SD | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Ghobrial, RM; Goldstein, LI; Han, S; Ibrahim, AB; Oh, MK; Saab, S; Tong, MJ; Yersiz, H | 1 |
| Bacon, BR; Barange, K; Harley, H; Lin, A; Nelson, D; Shafran, SD; Shiffman, ML; Solá, R; Soman, A; Suter, F; Zeuzem, S | 1 |
| Bani-Sadr, F; Billaud, E; Cacoub, P; Carrat, F; Doll, J; Goderel, I; Penalba, C; Perronne, C; Pol, S; Welker, Y | 1 |
| Alobeid, B; Gaglio, PJ; Mears, JG; Schecter, JM | 1 |
| Berg, T; Hadziyannis, SJ; Jorga, K; Marcellin, P; Puoti, C; Snoeck, E; Swain, MG; Zarski, JP; Zeuzem, S | 1 |
| Esposito, S; Hamzeh, FM; Rustgi, VK; Shiffman, ML | 1 |
| Aguirrebengoa, K; Asensi, V; Barreiro, P; Cervantes, M; Echeverria, S; Garcia-Samaniego, J; Núñez, M; Ocampo, A; Pascual, A; Soriano, V | 1 |
| Bai, C; Collantes, R; Fang, Y; Farmer, D; Gujral, H; Gurung, C; Nader, FH; Ong, JP; Ramsey, L; Sjogren, M; Sjogren, R; Srishord, M; Terra, K; Younossi, ZM | 1 |
| Avidan, B; Bar-Meir, S; Bashari, D; Lurie, Y; Maor, Y; Martinowitz, U; Paritsky, M; Rachlis, Z; Safadi, R; Schapiro, JM; Segol, O | 1 |
| Hasegawa, Y; Homma, M; Inoue, Y; Kohda, Y; Kojima, H | 1 |
| Arizcorreta-Yarza, A; Collado, A; Fernández-Fuertes, E; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Lozano, F; Macías, J; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortoso, M; Valera-Bestard, B | 1 |
| Aikata, H; Aimitsu, S; Chayama, K; Imamura, M; Ishihara, H; Kawakami, H; Kawakami, Y; Kitamoto, M; Moriya, T; Nakanishi, T; Satoh, K; Takahashi, S; Takaki, S; Tsuji, K | 1 |
| De Tullio, D; Falasca, K; Mancino, P; Pizzigallo, E; Ucciferri, C; Vecchiet, J | 1 |
| Bourliere, M | 1 |
| Acero, D; Adrados, M; Figa, M; González-Huix, F | 1 |
| Blot, C; Mathurin, P; Moussalli, J; Opolon, P; Perrin, M; Plassart, F; Poynard, T; Thevenot, T | 1 |
| Ballaré, M; Farina, M; Negro, F; Tappero, G | 1 |
| Dedović, N; Dimitrijević, B; Savovski, K; Vranić, V | 1 |
| Benhamou, Y; Bochet, M; Bréchot, C; Chaix, ML; Fontaine, H; Katlama, C; Lagneaux, JL; Landau, A; Pialoux, G; Pol, S; Poynard, T; Zylberberg, H | 1 |
| Dieterich, DT; Hau, T; Kreiswirth, S; Talal, AH; Weisz, K | 1 |
| Chakrabarti, S; Collingham, KE; Fegan, CD; Holder, K; Milligan, DW; Osman, H | 1 |
| Fouchard-Hubert, I; Gergely, AE; Lafarge, P; Lunel-Fabiani, F | 1 |
| Burgart, LJ; Charlton, M; El-Amin, OM; Kremers, WK; Narayanan Menon, KV; Poterucha, JJ; Rosen, CB; Wiesner, RH | 1 |
| Briggiler, AM; Canonico, PG; Enria, DA; Levis, S; Maiztegui, JI; Vallejos, D | 1 |
| Amorico, MG; Baldini, EV; Bisetti, A; Pellegrino, M | 1 |
45 review(s) available for ribavirin and Anemia
| Article | Year |
|---|---|
Association between inosine triphosphatase rs1127354 polymorphisms and ribavirin-induced anaemia and outcome in hepatitis C virus-infected patients: A meta-analysis.
Topics: Anemia; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Inosine Triphosphatase; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2020 |
Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Anemia; Antiviral Agents; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2019 |
[Inosine triphosphatase gene polymorphism and ribavirin-related anemia in chronic hepatitis C patients].
Topics: Anemia; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Polymorphism, Genetic; Pyrophosphatases; Ribavirin | 2012 |
[Progress in hepatitis C treatment].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2013 |
Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.
Topics: Anemia; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2013 |
[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Drug Eruptions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Medical Futility; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Stevens-Johnson Syndrome; Viral Load | 2013 |
Management of anaemia and other treatment complications.
Topics: Anemia; Antiviral Agents; Contraindications; Drug Eruptions; Drug Therapy, Combination; Dysgeusia; Hemorrhoids; Hepatitis C, Chronic; Humans; Interferons; Oligopeptides; Patient Selection; Platelet Count; Polyethylene Glycols; Proline; Pruritus Ani; Ribavirin; Serum Albumin | 2013 |
Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Randomized Controlled Trials as Topic; Ribavirin; Young Adult | 2014 |
[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Metabolic Syndrome; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Risk Factors | 2014 |
Management strategies for hepatitis C virus infection in children.
Topics: Adult; Anemia; Antiviral Agents; Child; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2008 |
Taribavirin for the treatment of chronic hepatitis C.
Topics: Anemia; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hepatitis C, Chronic; Humans; Prodrugs; Ribavirin; Treatment Outcome | 2008 |
Ribavirin: current role in the optimal clinical management of chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Peginterferon and ribavirin in HCV: improvement of sustained viral response.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Depression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome | 2008 |
Use of agents stimulating erythropoiesis in digestive diseases.
Topics: Anemia; Erythropoiesis; Erythropoietin; Hematinics; Hepatitis C; Humans; Inflammatory Bowel Diseases; Ribavirin | 2009 |
Ribavirin monotherapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Viral Load | 2009 |
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2010 |
Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2009 |
Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Heart Failure; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Renal Insufficiency; Ribavirin; Treatment Outcome | 2011 |
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin; Viral Load | 2011 |
[New agents for the treatment of hepatitis C].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Discovery; Drug Eruptions; Drugs, Investigational; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain; Viral Nonstructural Proteins | 2012 |
Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Proline; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome | 2012 |
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Withholding Treatment | 2012 |
Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Treatment Failure; Treatment Outcome; Virus Replication; Young Adult | 2012 |
Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Standard of Care; Treatment Failure | 2012 |
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Topics: Algorithms; Anemia; Antiviral Agents; Clinical Protocols; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Time Factors; Viral Load | 2012 |
Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2012 |
Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2012 |
Hepatitis C therapy update.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Factors | 2012 |
Boceprevir and treatment of chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2013 |
Anemia management in patients with chronic viral hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Hematinics; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2013 |
[Prevention of adverse effects in ribavirin and interferon combination therapy].
Topics: Abnormalities, Drug-Induced; Anemia; Animals; Antiviral Agents; Cerebral Hemorrhage; Drug Eruptions; Drug Therapy, Combination; Feeding and Eating Disorders; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Tissue Distribution | 2004 |
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-11; Neutropenia; Patient Compliance; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Kidney Failure, Chronic; Liver Transplantation; Neutropenia; Patient Compliance; Recombinant Proteins; Recurrence; Renal Dialysis; Ribavirin | 2004 |
The role of physician extenders in managing patients with chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Neutropenia; Nurse Practitioners; Patient Compliance; Patient Education as Topic; Physician Assistants; Quality of Health Care; Ribavirin; Risk Factors; Social Support; Thrombocytopenia | 2004 |
Anemia during treatment of hepatitis C in HIV-infected patients.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Use of growth factors with antiviral therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Patient Compliance; Quality of Life; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Management of the hematologic complications of hepatitis C therapy.
Topics: Anemia; Antiviral Agents; Bone Marrow; Epoetin Alfa; Erythropoietin; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
[Complementary treatments of chronic viral hepatitis C].
Topics: Anemia; Antidepressive Agents; Antioxidants; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
Definition and management of anemia in patients infected with hepatitis C virus.
Topics: Anemia; Antiviral Agents; Cardiovascular System; Cognition Disorders; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemoglobins; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.
Topics: Anemia; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon Type I; Interferon-alpha; Nitric Oxide; Paroxetine; Peptide Hydrolases; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Thyroid Diseases | 2006 |
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Treatment Outcome; Viral Load | 2006 |
Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.
Topics: Anemia; Antiviral Agents; Erythropoietin; Humans; Oxidants; Ribavirin; Risk Factors | 2006 |
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
Topics: Anemia; Chemotherapy, Adjuvant; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hepatitis C; Humans; Interferons; MEDLINE; Neutropenia; Recombinant Proteins; Ribavirin | 2007 |
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Quality of Life; Recombinant Proteins; Ribavirin | 2007 |
Therapeutic issues in HIV/HCV-coinfected patients.
Topics: Anemia; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Liver Transplantation; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
62 trial(s) available for ribavirin and Anemia
| Article | Year |
|---|---|
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome | 2018 |
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors | 2013 |
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Topics: Algorithms; Anemia; Antiviral Agents; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Predictors of consent to pharmacogenomics testing in the IDEAL study.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Testing; Genetic Variation; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Genetic; Precision Medicine; Pyrophosphatases; Racial Groups; Recombinant Proteins; Ribavirin; Sex Characteristics; Treatment Outcome; Young Adult | 2013 |
Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Viral Load | 2013 |
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
Topics: Adult; Aged; Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Topics: Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Topics: Adult; Anemia; Antiviral Agents; Cell Count; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2015 |
Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 an
Topics: Adolescent; Adult; Aged; Anemia; Depression; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Male; Middle Aged; Placebos; Ribavirin; Simeprevir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Ribavirin | 2015 |
Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients.
Topics: Anemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Japan; Leukopenia; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transplant Recipients; Treatment Outcome | 2014 |
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythrocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Serum; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Topics: Acrylates; Aminoisobutyric Acids; Anemia; Antiviral Agents; Benzimidazoles; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Leucine; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Pyrophosphatases; Quinolines; Real-Time Polymerase Chain Reaction; Ribavirin; Thiazoles | 2015 |
Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Erythropoietin; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
Topics: Adult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; RNA, Viral; Withholding Treatment | 2016 |
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.
Topics: Adult; Alanine Transaminase; Anemia; Chemokine CXCL10; Dose-Response Relationship, Drug; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.
Topics: Anemia; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Oligopeptides; Proline; Ribavirin; Severity of Illness Index; Treatment Outcome | 2016 |
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Female; Follow-Up Studies; Hemoglobins; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
Topics: Anemia; Antiviral Agents; Chronic Disease; Creatinine; Darbepoetin alfa; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Liver Transplantation; Male; Pilot Projects; Postoperative Care; Prospective Studies; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.
Topics: Adult; Anemia; Antiviral Agents; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Topics: Adult; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Creatinine; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Hematocrit; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Topics: Adult; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Italy; Linear Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2011 |
Boceprevir for untreated chronic HCV genotype 1 infection.
Topics: Adult; Anemia; Antiviral Agents; Black People; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Boceprevir for previously treated chronic HCV genotype 1 infection.
Topics: Anemia; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
Topics: Anemia; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genomic Structural Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Response-guided telaprevir combination treatment for hepatitis C virus infection.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Exanthema; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2011 |
Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.
Topics: Adolescent; Anemia; Antiviral Agents; Child; Child, Preschool; Eicosapentaenoic Acid; Female; Hepatitis C, Chronic; Humans; Male; Ribavirin; Young Adult | 2012 |
Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Platelet Count; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Thrombocytosis | 2012 |
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Topics: Adult; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Internationality; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors | 2012 |
[Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C].
Topics: Adenosine Triphosphate; Anemia; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Glutathione; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reticulocyte Count; Ribavirin | 2003 |
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Probability; Recombinant Proteins; Reference Values; Ribavirin; Treatment Outcome | 2003 |
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Function Tests; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2004 |
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: a randomized controlled trial.
Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Herbal Medicine; Humans; Liver Function Tests; Male; Middle Aged; Plant Extracts; Ribavirin; Th1 Cells; Th2 Cells; Viral Load | 2005 |
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2005 |
Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.
Topics: Adult; Anemia; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Topics: Adult; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Zidovudine | 2006 |
Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C].
Topics: Adult; Aged; Anemia; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Thyroiditis; Treatment Outcome; Viral Load | 2006 |
Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Dietary Supplements; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.
Topics: Adult; Amantadine; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Pilot Projects; Prospective Studies; Ribavirin | 2007 |
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome | 2007 |
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
Topics: Adult; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Zidovudine | 2007 |
Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Depression; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Surveys and Questionnaires; Thrombocytopenia; Time Factors; Viral Load | 2008 |
Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Withholding Treatment; Zidovudine | 2008 |
A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Topics: Adult; Anemia; Antiviral Agents; Darbepoetin alfa; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
Topics: Adult; Aged; Anemia; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2007 |
A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha.
Topics: Anemia; Antiviral Agents; Erythropoietin; Humans; Interferon-alpha; Pilot Projects; Prospective Studies; Ribavirin | 2001 |
Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2002 |
[New therapeutic strategies in influenza infections in patients at risk. Controlled study of ribavirin].
Topics: Aged; Aged, 80 and over; Anemia; Clinical Trials as Topic; Double-Blind Method; Humans; Influenza, Human; Middle Aged; Random Allocation; Ribavirin; Ribonucleosides; Risk Factors | 1987 |
155 other study(ies) available for ribavirin and Anemia
| Article | Year |
|---|---|
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Brazil; Carbamates; Drug Therapy, Combination; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2019 |
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
Topics: Aged; Anemia; Antiviral Agents; California; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Sex Factors; Sofosbuvir; Viral Load | 2017 |
The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients.
Topics: Adult; Anemia; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Prognosis; Pyrophosphatases; Ribavirin | 2017 |
Treatment of chronic Hepatitis C in Thalassemia major patients.
Topics: Adolescent; Adult; Anemia; Antiviral Agents; beta-Thalassemia; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Pilot Projects; Ribavirin; RNA, Viral; Sustained Virologic Response; Young Adult | 2017 |
Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy.
Topics: Adult; Age Factors; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferons; Male; Middle Aged; Pakistan; Ribavirin; Risk Factors; Sex Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase.
Topics: Adenosine Triphosphate; Anemia; Antiviral Agents; Dehydroepiandrosterone; Erythrocytes; Glucosephosphate Dehydrogenase; Hemolysis; Hepatitis C, Chronic; Humans; Pentose Phosphate Pathway; Ribavirin | 2017 |
Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Enzyme Induction; Female; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Pyrophosphatases; Ribavirin | 2018 |
Anti-anemia effects of ginsenoside Rk3 and ginsenoside Rh4 on mice with ribavirin-induced anemia.
Topics: Anemia; Animals; Erythrocyte Count; Female; Ginsenosides; Hemoglobins; Humans; Male; Mice; Mice, Inbred BALB C; Ribavirin | 2018 |
Ribavirin therapy of hepatitis E infection may cause hyporegenerative anemia in pediatric renal transplant patients.
Topics: Adolescent; Anemia; Antiviral Agents; Chronic Disease; Female; Hepatitis E; Humans; Kidney Transplantation; Postoperative Complications; Ribavirin | 2018 |
Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis.
Topics: Adult; Anemia; Darbepoetin alfa; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Renal Dialysis; Ribavirin; Tacrolimus; Treatment Outcome | 2018 |
Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults.
Topics: Aged; Aged, 80 and over; Anemia; Antiviral Agents; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2018 |
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
Topics: Aged; Anemia; Antiviral Agents; Dizziness; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
Topics: Adult; Anemia; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2022 |
Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies.
Topics: Adult; Anemia; Antiviral Agents; Comorbidity; Delivery of Health Care, Integrated; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interprofessional Relations; Male; Middle Aged; Personality Disorders; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin; Sofosbuvir; Substance-Related Disorders | 2019 |
Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon.
Topics: Anemia; Antiviral Agents; Asian People; Drug Combinations; Female; Forecasting; Hemoglobins; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Pyrophosphatases; Ribavirin | 2020 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine | 2019 |
Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Risk Factors | 2013 |
Anemia as a predictor of response to antiviral therapy in chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Treatment Outcome; Veterans; Viral Load | 2013 |
Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Egypt; Female; Gene Frequency; Genetic Predisposition to Disease; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome | 2013 |
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.
Topics: Anemia; Erythropoietin; Escherichia coli; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-6; Ligands; Lipopolysaccharides; Monocytes; Phagocytosis; Reactive Oxygen Species; Receptors, Erythropoietin; Ribavirin; RNA, Messenger; Toll-Like Receptor 4 | 2013 |
Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Thrombocytopenia; Young Adult | 2013 |
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
Topics: Adult; Alleles; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Homozygote; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Premenopause; Pyrophosphatases; Recombinant Proteins; Ribavirin; Sex Factors | 2013 |
Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Fatigue; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Mental Health; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2014 |
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
Topics: Adult; Anemia; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin; Treatment Outcome | 2013 |
Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Serum | 2014 |
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Viral Load | 2014 |
HCV, ribavirin, and anemia: a new dawn.
Topics: Anemia; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retinal Diseases; Ribavirin | 2014 |
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Topics: Anemia; Diabetes Mellitus, Type 2; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Statistics, Nonparametric | 2014 |
Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
Topics: Administration, Oral; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2014 |
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2013 |
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Metabolism, Inborn Errors; Middle Aged; Pyrophosphatases; Ribavirin; Treatment Outcome | 2013 |
DHEA and progesterone have a protective effect on ribavirin-induced hemolysis.
Topics: Anemia; Female; Hepatitis C, Chronic; Humans; Male; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sex Factors | 2014 |
Reply to: "DHEA and progesterone have a protective effect on ribavirin-induced hemolysis".
Topics: Anemia; Female; Hepatitis C, Chronic; Humans; Male; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sex Factors | 2014 |
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Treatment Outcome | 2014 |
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
Topics: Anemia; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Fatigue; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Economic; Multicenter Studies as Topic; Oligopeptides; Outcome Assessment, Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2014 |
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Cell Differentiation; Cell Proliferation; Erythroid Cells; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult | 2014 |
ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Early Diagnosis; Female; Fibrosis; Genetic Variation; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin | 2014 |
[Management of side effects induced by antiviral therapy for chronic hepatitis infection].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hematinics; Hepatitis C, Chronic; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; Treatment Outcome | 2013 |
Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Prospective Studies; Renal Insufficiency; Retrospective Studies; Ribavirin; Risk Factors | 2014 |
Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hematologic Diseases; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin; Taiwan; Thrombocytopenia | 2015 |
[Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
Topics: Anemia; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Oligopeptides; Polyethylene Glycols; Prevalence; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; Spain | 2014 |
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
Topics: Anemia; Antiviral Agents; Bilirubin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Neutropenia; Prevalence; Pruritus; Ribavirin; Simeprevir | 2015 |
Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
Topics: Acute Kidney Injury; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2015 |
Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus.
Topics: Adult; Aged; Anemia; Antiviral Agents; Biomarkers; Drug Eruptions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Renal Insufficiency; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2014 |
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin | 2015 |
Recombinant Human Erythropoietin (RHuEpo) and Granular Colony Stimulating Factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description.
Topics: Anemia; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Erythropoietin; Glomerulonephritis, Membranoproliferative; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2014 |
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genetic Predisposition to Disease; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin | 2015 |
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Topics: Anemia; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; France; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Proline; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Anemia; Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Receptors, Calcitriol; Retrospective Studies; Ribavirin; Vitamin D3 24-Hydroxylase | 2015 |
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.
Topics: Age Factors; Aged; Anemia; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Glomerular Filtration Rate; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyrophosphatases; Retrospective Studies; Ribavirin; Risk; Severity of Illness Index; Simeprevir; Viral Nonstructural Proteins | 2015 |
Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Neutropenia; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Republic of Korea; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Common adverse events associated with ribavirin therapy for Severe Fever with Thrombocytopenia Syndrome.
Topics: Anemia; Antiviral Agents; Female; Hemoglobins; Humans; Hyperamylasemia; Male; Middle Aged; Phlebotomus Fever; Phlebovirus; Prospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2015 |
Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.
Topics: Aged; Anemia; Antiviral Agents; Erythrocyte Transfusion; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Middle Aged; Mycophenolic Acid; Recurrence; Ribavirin; Simeprevir; Tacrolimus | 2015 |
Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cohort Studies; DNA; Female; Genotype; Hepatitis C; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Young Adult | 2015 |
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepatitis C, Chronic; Humans; Incidence; Male; Membrane Transport Proteins; Middle Aged; Oligopeptides; Proline; Prospective Studies; Protease Inhibitors; Pyrophosphatases; Ribavirin; Risk Assessment; Young Adult | 2015 |
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythrocyte Indices; Erythrocyte Membrane; Erythropoiesis; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin; Treatment Outcome | 2016 |
Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Pyrophosphatases; Ribavirin; Sensitivity and Specificity; Treatment Outcome | 2015 |
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
Topics: Adult; Aged; Anemia; Antiviral Agents; Databases, Factual; Drug Costs; Drug Eruptions; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; United States | 2015 |
Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Brazil; Case-Control Studies; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2015 |
Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome; Tunisia; Viral Load | 2015 |
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin | 2015 |
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin | 2016 |
[Telaprevir, peginterferon and ribavirin therapy for chronic hepatitis C].
Topics: Anemia; Drug Combinations; Hepatitis C, Chronic; Humans; Interferons; Kidney Function Tests; Oligopeptides; Ribavirin | 2015 |
Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Egypt; Female; Genetic Association Studies; Genotyping Techniques; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Real-Time Polymerase Chain Reaction; Ribavirin; Thrombocytopenia; Young Adult | 2016 |
Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.
Topics: Anemia; Antiviral Agents; Computer Simulation; Dose-Response Relationship, Drug; Erythrocytes; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Models, Biological; Pyrophosphatases; Ribavirin | 2016 |
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation | 2016 |
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
Topics: Anemia; Antiviral Agents; Coinfection; Decision Support Techniques; Drug Therapy, Combination; Female; Genotyping Techniques; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Male; Membrane Transport Proteins; Oligopeptides; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Proline; Ribavirin | 2016 |
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Sustained Virologic Response; Time Factors; Treatment Failure; Young Adult | 2016 |
Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Retrospective Studies; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Young Adult | 2016 |
Pharmacogenetics of ribavirin-induced anemia in hepatitis C.
Topics: Anemia; Antiviral Agents; Equilibrative Nucleoside Transporter 1; Hepatitis C; Humans; Membrane Transport Proteins; Pharmacogenetics; Ribavirin | 2016 |
Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cardiovascular Diseases; Eligibility Determination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Netherlands; Neutropenia; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2016 |
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dehydroepiandrosterone; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Young Adult | 2017 |
ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
Topics: Aged; Alleles; Anemia; Antiviral Agents; Disease Susceptibility; Drug Therapy, Combination; Enzyme Activation; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Liver Cirrhosis; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Risk Factors; Severity of Illness Index | 2017 |
Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Topics: Adult; Anemia; Antiviral Agents; Cardiovascular Diseases; Female; Hematinics; Hemoglobins; Hepatitis C; Humans; Interferons; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
[Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2008 |
Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.
Topics: Adolescent; Anemia; Antiviral Agents; Chelation Therapy; Deferoxamine; Ferritins; Hemoglobinopathies; Hemosiderosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Siderophores | 2009 |
Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Neutropenia; Ribavirin; Risk Factors; Thrombocytopenia | 2010 |
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Topics: Adolescent; Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Leukocyte Count; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; RNA, Viral; Saudi Arabia | 2011 |
ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Genome-Wide Association Study; Hepatitis C; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2010 |
Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.
Topics: Adenosine Triphosphate; Adenylosuccinate Synthase; Adolescent; Adult; Anemia; Antiviral Agents; Enzyme Activation; Erythrocytes; Genetic Variation; Genotype; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; In Vitro Techniques; Inosine Triphosphatase; Inosine Triphosphate; Pyrophosphatases; Ribavirin; Young Adult | 2011 |
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin | 2011 |
Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients.
Topics: Anemia; Antiviral Agents; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome; Viral Load | 2011 |
A new era of hepatitis C therapy begins.
Topics: Anemia; Antiviral Agents; Black People; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors | 2011 |
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
Topics: Amino Acid Substitution; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins | 2011 |
Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Zidovudine | 2011 |
Boceprevir for chronic HCV genotype 1 infection.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2011 |
Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prevalence; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome | 2011 |
Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Pilot Projects; Premedication; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Assessment | 2011 |
Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
Topics: Adult; Aged; Alleles; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Serotyping | 2012 |
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Topics: Adult; Anemia; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferon alpha-2; Interferon-alpha; Oseltamivir; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.
Topics: Administration, Oral; Anemia; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Taiwan | 2012 |
Low hemoglobin A(1c)--good diabetic control?
Topics: Anemia; Diabetes Mellitus, Type 2; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C; Humans; Insulin Glargine; Insulin, Long-Acting; Interferon-alpha; Metformin; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Risk Factors | 2012 |
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Ribavirin; Thrombocytopenia; Young Adult | 2012 |
Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).
Topics: Adult; Aged; Anemia; Cohort Studies; Female; Gene Expression Profiling; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Polymorphism, Genetic; Pyrophosphatases; Ribavirin | 2012 |
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
Topics: Adult; Anemia; Antiviral Agents; Coinfection; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Ribavirin; Treatment Outcome | 2012 |
Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2012 |
Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
Topics: Alanine Transaminase; Anemia; Antiviral Agents; Biomarkers; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Hearing Loss, Sudden; Hearing Loss, Unilateral; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms.
Topics: Algorithms; Anemia; Antiviral Agents; Hemoglobins; Hepatitis C, Chronic; Humans; Models, Biological; Polymorphism, Genetic; Pyrophosphatases; Reproducibility of Results; Ribavirin | 2012 |
HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Histocompatibility Testing; HLA-B15 Antigen; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA | 2012 |
Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Renal Dialysis; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
Topics: Anemia; Antiviral Agents; Cohort Studies; Female; Genetic Association Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Male; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2013 |
Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prognosis; Pyrophosphatases; Ribavirin; Treatment Failure | 2013 |
Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus.
Topics: Anemia; Anti-HIV Agents; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin | 2001 |
Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.
Topics: Adult; Analysis of Variance; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2002 |
A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Eicosapentaenoic Acid; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Reticulocyte Count; Ribavirin | 2003 |
Anemia in the treatment of hepatitis C virus infection.
Topics: Anemia; Antiviral Agents; Epoetin Alfa; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2003 |
Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.
Topics: Adult; Aged; Anemia; Antiviral Agents; Creatinine; Dose-Response Relationship, Drug; Female; Hemoglobins; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Function Tests; Male; Middle Aged; Plasma; Recombinant Proteins; Ribavirin | 2004 |
Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia.
Topics: Anemia; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocytes; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index | 2004 |
Role of epoetin alfa in maintaining ribavirin dose.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
[Therapy with interferon plus ribavirin in hemodialysis patient with PCR-positive viral hepatitis C].
Topics: Adult; Anemia; Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Polymerase Chain Reaction; Renal Dialysis; Ribavirin; RNA, Viral; Vesico-Ureteral Reflux; Viremia | 2004 |
Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematocrit; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: correlations with ribavirin induced anemia.
Topics: Adenosylhomocysteinase; Anemia; Animals; Antiviral Agents; Erythrocytes; Hepatitis C, Chronic; Humans; Models, Biological; Ribavirin; S-Adenosylhomocysteine; S-Adenosylmethionine; Statistics as Topic | 2004 |
Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Treatment of chronic hepatitis C in a patient with systemic lupus erythematosus.
Topics: Aged; Anemia; Antiviral Agents; Asthenia; Drug Therapy, Combination; Female; Headache; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Lupus Erythematosus, Systemic; Ribavirin | 2004 |
Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Bayes Theorem; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocyte Count; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Biological; Retrospective Studies; Ribavirin | 2005 |
Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers.
Topics: Adult; Anemia; Antiviral Agents; Chi-Square Distribution; Communicable Diseases, Emerging; Female; Humans; Hypoxia; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Severe Acute Respiratory Syndrome; Statistics, Nonparametric; Taiwan; Treatment Outcome | 2005 |
Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Linear Models; Male; Ribavirin | 2005 |
Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia.
Topics: Adult; Anemia; Antiviral Agents; Disulfides; Erythrocyte Membrane; Erythrocytes; Female; Glutathione Peroxidase; Hemolysis; Hepatitis C; Humans; In Vitro Techniques; Male; Membrane Proteins; Middle Aged; Oxidative Stress; Predictive Value of Tests; Ribavirin; Sulfhydryl Compounds; Thioredoxins | 2005 |
The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
Topics: Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Darbepoetin alfa; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2005 |
Depression, anemia and health-related quality of life in chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Depression; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Risk Factors; Surveys and Questionnaires | 2006 |
[Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2006 |
Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
Topics: Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Blood Cell Count; Blood Platelets; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Quebec; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2006 |
Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
Topics: Age Factors; Anemia; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Treatment Outcome | 2006 |
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
Topics: Anemia; Cost-Benefit Analysis; Darbepoetin alfa; Decision Trees; Drug Therapy, Combination; Erythropoietin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Markov Chains; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.
Topics: Adolescent; Adult; Aged; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Black People; Cell Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Hispanic or Latino; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Protease Inhibitors; Recombinant Proteins; Reticulocytes; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors; Treatment Outcome; White People; Zidovudine | 2007 |
Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome.
Topics: Adrenal Cortex Hormones; Adult; Adverse Drug Reaction Reporting Systems; Anemia; Antiviral Agents; Bradycardia; Canada; Cohort Studies; Disease Outbreaks; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Magnesium Deficiency; Male; Medical Records Systems, Computerized; Middle Aged; Retrospective Studies; Ribavirin; Severe Acute Respiratory Syndrome; Tetany; Treatment Outcome | 2007 |
Anemia and clinical outcomes in hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Ribavirin; Treatment Outcome | 2007 |
The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
Topics: Algorithms; Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Erythropoietin; Genotype; Health Care Costs; Health Resources; Hepatitis C; Humans; Models, Theoretical; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.
Topics: Adult; Analysis of Variance; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2007 |
Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus.
Topics: Anemia; Antibodies; Antiviral Agents; Epoetin Alfa; Erythropoietin; Graft Rejection; Hematinics; Hepatitis C; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Prednisone; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin; Secondary Prevention; Tacrolimus | 2007 |
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Topics: Alanine Transaminase; Anemia; Computer Simulation; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Models, Theoretical; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hemorrhage; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Israel; Liver; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Blood ribavirin concentration in high-dose ribavirin for adenovirus-induced haemorrhagic cystitis - a case report.
Topics: Adenoviridae; Adenoviridae Infections; Anemia; Antiviral Agents; Blood Transfusion; Cystitis; Drug Monitoring; Drug Therapy, Combination; Erythrocytes; Hemoglobins; Hemorrhage; Humans; Immunoglobulins, Intravenous; Male; Middle Aged; Ribavirin; Stem Cell Transplantation | 2008 |
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Spain; Thrombocytopenia; Zidovudine | 2007 |
High dose of erythropoietin in management of interferon/ribavirin induced anemia.
Topics: Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Erythropoietin; Female; Hematocrit; Hemoglobins; Hepatitis C; Humans; Middle Aged; Recombinant Proteins; Ribavirin | 2007 |
[Treatment of hepatitis C: therapeutic management].
Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin | 2008 |
[Ribavirin treatment in patients with chronic hepatitis C refractory to interferon-alpha].
Topics: Adult; Anemia; Antiviral Agents; Chronic Disease; Drug Evaluation; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Transaminases | 1996 |
Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Azathioprine; Chronic Disease; Contraindications; Drug Therapy, Combination; Female; Hemoglobins; Hemolysis; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Retrospective Studies; Ribavirin | 1997 |
Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 1998 |
Hematological toxicity associated with tiazofurin-influence on erythropoiesis.
Topics: Alopecia; Anemia; Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Blood Cells; Bone Marrow Cells; Cachexia; Cell Count; Coma; Dose-Response Relationship, Drug; Erythropoiesis; Hematocrit; Hemoglobins; Lung; Male; Rats; Rats, Wistar; Ribavirin; Spleen; Splenomegaly; Survival Rate | 2000 |
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Topics: Adult; Anemia; Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymerase Chain Reaction; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2000 |
Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study.
Topics: Administration, Oral; Adult; Anemia; Anemia, Aplastic; Antiviral Agents; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Male; Middle Aged; Nausea; Parainfluenza Virus 3, Human; Pilot Projects; Pneumonia, Viral; Population Surveillance; Prospective Studies; Respiratory Syncytial Virus Infections; Respirovirus Infections; Ribavirin; Transplantation Conditioning; Treatment Outcome | 2001 |
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Protocols; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.
Topics: Anemia; Female; Hematocrit; Hemoglobins; Hemorrhagic Fever, American; Humans; Interferons; Male; Prospective Studies; Ribavirin; Ribonucleosides; Viremia | 1987 |